Triplenegative breast cancers (TNBCs) have historically been among the most difficult to treat, but the availability of new drugs, and an increased understanding of the molecular nature of TNBC is beginning to expand treatment options in this breast cancer subset. In this session, Dr Ilana Schlam from Tufts Medical Center discusses strategies for treatment planning in TNBC.

To obtain credit for this CME activity you must watch the full 2022 Evolution Conference Playlist. Information on obtaining CME/CE Credits and MOC points can be found in the playlist description.